28948-60-9

Basic information

• Product Name: 2-Bromothieno[3,2-c]pyridin-4(5H)-one
• Synonyms: 2-Bromothieno[3,2-c]pyridin-4(5H)-one;2-broMo-4H,5H-thieno[3,2-c]pyridin-4-one;2-BroMothieno[3,2-c]pyridin-4-ol;2-Bromo-5H-thieno[3,2-c]pyridin-4-one
• CAS NO: 28948-60-9
• Molecular Formula: C₇H₄BrNOS
• Molecular Weight: 230.085
• EINECS: 604-604-1
• Mol File: 28948-60-9.mol

Chemical Properties

• Boiling Point: 461.674 °C at 760 mmHg
• Flash Point: 233.012 °C
• Appearance: /
• Density: 1.801 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.12±0.20(Predicted)
• CAS DataBase Reference: 2-Bromothieno[3,2-c]pyridin-4(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromothieno[3,2-c]pyridin-4(5H)-one(28948-60-9)
• EPA Substance Registry System: 2-Bromothieno[3,2-c]pyridin-4(5H)-one(28948-60-9)

Safety Data

• Hazardous Substances Data: 28948-60-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-bromothieno[3,2-c]pyridin-4(5H)-one is used as a building block for the synthesis of pharmaceutical compounds due to its unique structure and properties. Its heterocyclic nature and bromine atom provide opportunities for the development of new drugs with potential therapeutic applications.
Used in Materials Science:
In the field of materials science, 2-bromothieno[3,2-c]pyridin-4(5H)-one is utilized as a component in the development of novel materials with specific properties. Its chemical structure allows for the creation of materials with tailored characteristics for various applications, such as in electronics, sensors, or other advanced technologies.
Used in Organic Chemistry Research:
2-bromothieno[3,2-c]pyridin-4(5H)-one serves as a versatile compound in organic chemistry research, where its reactivity and potential for functionalization are exploited to explore new synthetic pathways and develop innovative chemical reactions. This contributes to the advancement of organic chemistry and the discovery of new compounds with diverse applications.

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 50868-68-3 (E)-3-(5-bromo-2-thienyl)-2-propenoic acid 
• 29079-97-8 3-(5-Bromo-2-thienyl)acrylic acid 
• 4701-17-1 5-bromo-2-thiophencarboxaldehyde 
• 636999-00-3 (2E)-3-(5-bromothien-2-yl)acryloyl azide 

Downstream Products

• 28948-61-0 2-bromo-4-chlorothieno[3,2-c]pyridine 
• 690636-03-4 2-phenylthieno[3,2-c]pyridin-4(5H)-one 
• 1333107-87-1 C₁₂H₈N₂OS 
• 1333107-77-9 C₁₉H₁₀FN₃OS 
• 1333107-78-0 C₂₀H₁₄N₂O₃S 
• 1333107-79-1 C₂₀H₁₃N₃OS 
• 1333107-80-4 C₁₇H₁₀ClN₃OS 
• 1333107-81-5 C₁₇H₉N₃OS₂ 
• 1333107-82-6 C₂₀H₁₆N₂O₂S 
• 1333107-83-7 C₁₉H₁₅N₃O₂S 
• 1333107-84-8 C₁₉H₁₃FN₂O₂S 
• 1333107-85-9 C₂₁H₁₇N₃O₂S 
• 1333107-86-0 C₂₁H₁₃N₃OS 
• 1333107-70-2 7-bromo-2-pyridin-4-yl-5h-thieno[3,2-c]pyridin-4-one 

Relevant articles and documents

Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway

We developed JMS-053, a potent inhibitor of the dual specificity phosphatase PTP4A3 that is potentially suitable for cancer therapy. Due to the emerging role of the unfolded protein response (UPR) in cancer pathology, we sought to identify derivatives that combine PTP4A3 inhibition with induction of endoplasmatic reticulum (ER) stress, with the goal to generate more potent anticancer agents. We have now generated bifunctional analogs that link the JMS-053 pharmacophore to an adamantyl moiety and act in concert with the phosphatase inhibitor to induce ER stress and cell death. The most potent compound in this series, 7a, demonstrated a ca. 5-fold increase in cytotoxicity in a breast cancer cell line and strong activation of UPR and ER stress response genes in spite of a ca. 13-fold decrease in PTP4A3 inhibition. These results demonstrate that the combination of phosphatase inhibition with UPR/ER-stress upregulation potentiates efficacy.

IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS

The disclosure provides compounds that inhibit protein tyrosine phosphatase, such as protein tyrosine phosphatase 4A3 (PTP4A3). The disclosure also provides pharmaceutical compositions, uses, and methods of using the compounds, such as in the treatment of cancers. (I), wherein X is O or NH.

BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are a benzazepine derivative, a preparation method, a pharmaceutical composition and the use thereof. A compound as shown in formula (I) of the present invention, and an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof have the following structure. The benzazepine derivative of the present invention has a good regulation effect on the TLR family and the related signalling pathway, and in particular, has a good regulation effect on TLR8, can effectively treat, relieve and/or prevent various diseases mediated by TLR family and the TLR-related signalling pathway, and in particular, can effectively treat, relieve and/or prevent various diseases mediated by TLR8, such as cancers, autoimmune diseases, infections, inflammations, transplantation rejections, graft-versus-host diseases, etc.

In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors

A continuous flow photooxygenation of 7-aminothieno[3,2-c]pyridin-4(5H)-ones to produce 7-iminothieno[3,2-c]pyridine-4,6(5H,7H)-diones has been developed, utilizing ambient air as the sole reactant. N-H Imines are formed as the major products, and excellent functional group tolerance and conversion on gram-scale without the need for chromatographic purification allow for facile late-stage diversification of the aminothienopyridinone scaffold. Several analogs exhibit potent in vitro inhibition of the cancer-associated protein tyrosine phosphatase PTP4A3, and the SAR supports an exploratory docking model.

Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors

The discovery of a novel series of 2-(4-pyridyl)thienopyridinone GSK-3β inhibitors is reported. X-ray crystallography reveals its binding mode and enables rationalization of the SAR. The initial optimization of the template for improved cellular activity and predicted CNS penetration is also presented.

Antiinflammation agents

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.

NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS

The present invention relates to compounds of the general formula (I), wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R3 are as defined in the description;to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and of body weight gain.